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Abstract
Gefitinib is a specific inhibitor of the epidermal growth
factor receptor (EGFR) that causes growth delay in cancer
cell lines and human tumor xenografts expressing high
levels of EGFR. An understanding of the downstream
cellular targets of gefitinib will allow the discovery of
biomarkers for predicting outcomes and monitoring anti-
EGFR therapies and provide information for key targets for
therapeutic intervention. In this study, we investigated the
role of FOXO3a in gefitinib action and resistance. Using
two gefitinib-sensitive (i.e., BT474 and SKBR3) as well
as three other resistant breast carcinoma cell lines (i.e.,
MCF-7, MDA-MB-231, and MDA-MB-453), we showed
that gefitinib targets the transcription factor FOXO3a to
mediate cell cycle arrest and cell death in sensitive breast
cancer cells. In the sensitive cells, gefitinib treatment
causes cell cycle arrest predominantly at the G0-G1 phase
and apoptosis, which is associated with FOXO3a dephos-
phorylation at Akt sites and nuclear translocation, where-
as in the resistant cells, FOXO3a stays phosphorylated
and remains in the cytoplasm. The nuclear accumulation
of FOXO3a in response to gefitinib was confirmed in
tumor tissue sections from breast cancer patients presur-
gically treated with gefitinib as monotherapy. We also
showed that knockdown of FOXO3a expression using
small interfering RNA (siRNA) can rescue sensitive BT474
cells from gefitinib-induced cell-proliferative arrest, where-
as reintroduction of active FOXO3a in resistant MDA-MB-
231 cells can at least partially restore cell-proliferative
arrest and sensitivity to gefitinib. These results suggest
that the FOXO3a dephosphorylation and nuclear localiza-
tion have a direct role in mediating the gefitinib-induced
proliferative arrest and in determining sensitivity to
gefitinib. [Mol Cancer Ther 2007;6(12):3169–79]
Introduction
Breast cancer is the most common cancer in women in
industrialized countries and is the second biggest killer
after lung cancer (1). Research has shown that the
inappropriate activation of growth factor–signaling cas-
cades can support hormone-independent tumor cell
growth and promote endocrine therapy resistance in breast
cancer. Increased growth factor signaling has also been
associated with estrogen-receptor–negative diseases and,
hence, poor prognosis (2–5).
The recent availability of tyrosine kinase inhibitors (TKI)
that specifically block the phosphorylation and function of
epidermal growth factor receptor (EGFR) and HER2 has
provided a novel therapeutic strategy. One such inhibitor is
ZD1839/gefitinib (Iressa), a selective EGFR-TKI, and
another is GW572016/lapatinib, a dual inhibitor of EGFR
and HER2. These inhibitors act through competitive
inhibition of ATP binding to the receptor tyrosine kinase
domain (2, 4, 6). Both gefitinib and lapatinib can cause
growth delay in cancer cell lines and human tumor
xenografts expressing high levels of EGFR or HER2 and
can significantly potentiate the antiproliferative effects of
anti-estrogens and conventional chemotherapeutic drugs
when used in combination (7, 8). Recent phase II/III clinical
studies have shown that both gefitinib and lapatinib were
well tolerated and provided antitumor activity in patients
with breast cancer as well as with other types of cancer
when used as a monotherapy or in combination with other
therapies (7–10). However, the clinical data also showed
that not all patients respond to the inhibitors, indicating
the existence of an intrinsic or de novo resistance to the drug
(5, 10, 11). In some clinical studies, the absence of direct
association between EGFR expression levels and response
to the therapy with gefitinib and lapatinib was noted
(10, 12, 13). Indeed, even high EGFR expression per se was
not sufficient to determine sensitivity to gefitinib because
molecular defects in downstream signaling pathways
might impair transmission of the signal and, thus, the
action of the drug (14).
The activation of EGFR/erbB2 tyrosine kinases results in
the activation of extracellular signal-regulated kinase 1/2
(ERK 1/2) mitogen-activated protein (MAP) kinases
and phosphoinositide-3-kinase (PI3K)/protein kinase B
(PKB, also called Akt) signaling pathway (10, 14, 15). The
PI3K/Akt tumor suppressor signaling pathway plays an
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important role in the growth, survival, and development of
normal and malignant cells (16, 17). One of the downstream
targets of the PI3K/Akt signaling pathway is the Forkhead/
winged helix box class O protein FOXO3a (formerly termed
FKHRL-1; ref. 18). Activated Akt directly controls the
activity of FOXO3a through phosphorylation, leading to
its translocation to the cytoplasm, where it is sequestered by
the 14-3-3 chaperone protein (18). Inhibition of Akt leads to
dephosphorylation and nuclear localization of FOXO3a,
resulting in its activation. Studies in mammalian cells have
shown that the activation of FOXO3a induces cell cycle
arrest and/or apoptosis through the up-regulation of its key
target genes such as p27Kip1 and Bim (19–22). An
understanding of the downstream cellular targets of gefiti-
nib will allow the discovery of markers that can serve to




The human breast carcinoma cell lines BT474, SKBR3,
MCF-7, MDA-MB-231, and MDA-MB-453 were maintained
in DMEM supplemented with 10% fetal bovine serum,
2 mmol/L glutamine, and 100 units/mL penicillin-
streptomycin at 37jC. Gefitinib (Iressa) was obtained from
AstraZeneca and dissolved in DMSO to give 30 mmol/L
stock solution for cell culture work.
Proliferation Assay
Cells were counted and plated at the same initial density
on 24-well plates. They were then treated with 5 Amol/L
gefitinib or the vehicle only and incubated for time periods
ranging from 0 to 72 h. At each time point, cells were
trypsinized and counted using a Neubauer hemocytometer
under trypan blue exclusion.
Cell CycleAnalysis
Cell cycle analysis was done using propidium iodide
staining. For this, cells were trypsinized, washed in PBS,
and then fixed in 90% ethanol. Fixed cells were then washed
twice in PBS and stained with 50 Amol/L propidium iodide
in PBS containing 5 Ag/mL DNase-free RNase for 1 h and
then analyzed by flow cytometry using a FACS canto (BD
Biosciences) and FACSDiva software (BD Biosciences).
Western Blotting
Western blotting was done on whole cell extracts prepared
by lysing cells in NP40 lysis buffer [1% NP40, 100 mmol/L
NaCl, 20 mmol/L Tris-HCl (pH 7.4), 10 mmol/L NaF,
1 mmol/L sodium orthovanadate, 30 mmol/L Na h-
glycerophosphate, and protease inhibitors (‘‘Complete’’
protease inhibitor mixture, as instructed by the manufac-
turer, Roche Applied Science)] on ice for 15 min. Insoluble
material was removed by centrifugation, and protein
concentration was determined by Bio-Rad Dc protein assay.
Twenty micrograms of protein was size fractionated using
SDS-PAGE and electro-transferred onto Protran nitrocellu-
lose membranes (Schliecher and Schuell). Membranes
were blocked in 5% bovine serum albumin (BSA) or 5%
milk in TBS plus 0.5% Tween for 30 min at room temperature
and then incubated with specific antibodies. Antibodies
recognizing total FOXO3a were purchased from Upstate.
Antibodies specific for FOXO3a (Thr24)/FOXO3a phosphor-
ylated at Thr32, Akt phosphorylated at the Ser473, total Akt,
ERK 1/2 phosphorylated at Thr202/204, total ERK 1/2, were
purchased from Cell Signaling Technologies. Antibody to
Bin was purchased from Calbiochem (Merck), anti-actin was
from Santa Cruz Biotechnology (Autogen Bioclear), and
anti-lamin was from Abcam. The mouse monoclonal
antibody recognizing human p27Kip1 has previously been
described (23). Primary antibodies were detected using
horseradish peroxidase–linked anti-mouse or anti-rabbit
conjugates as appropriate (DAKO) and visualized using the
enhanced chemiluminescence detection system (Amersham
Biosciences). Quantitation of phospho (P)-FOXO3a, P-Akt,
and P-ERK 1/2 protein expression was done using ImageJ
software (Image Processing and Analysis in Java).
Preparation of Nuclear and Cytoplasmic Extracts
Cells were lysed on ice for 20 min in cytosolic buffer
(10 mmol/L HEPES, 10 mmol/L KCl, 0.1 mmol/L EDTA,
0.1 mmol/L EGTA, 2 mmol/L DTT), after which NP40 was
added to a final concentration of 1%, and then the cells
were vortexed for 10 s. Nuclei were sedimented by 30 s
centrifugation at 13,000  g , and the supernatant contain-
ing the cytoplasmic fraction was snap frozen. The pellet,
containing the nuclei, was resuspended in cytosolic buffer
with 400 mmol/L NaCl and 1% NP40 and rotated at
maximum speed on a wheel at 4jC for 15 min. The samples
were then centrifuged at 4jC for 5 min at 13,000  g . The
supernatant containing the nuclear fraction was snap
frozen and kept at 70jC.
Immunofluorescence
Cells were grown on sterile, 13-mm-diameter coverslips
and fixed in 4% formaldehyde before being permeabilized
in 0.01% v/v Triton X-100. Coverslips were blocked in PBS
containing 3% BSA, and antibody recognizing FOXO3a
(Upstate) was added at 50 Ag/mL. Specific staining was
visualized with a secondary antibody conjugated to Alexa
488 (anti-rabbit; Molecular Probes) and analyzed on a Zeiss
confocal microscope with LSM meta 510 software.
Gene Silencingwith Small Interfering RNAs
For gene silencing, cells were transiently transfected with
50 nmol/L of the following small interfering RNA (siRNA)
reagents purchased from Dharmacon: FOXO3a siGENOME
SMARTpool or Non-Targeting siRNA Pool. BT474 cells
were cultured in six-well plates until 60% confluent and
were transfected with 100 pmol/L of annealed oligonu-
cleotides using OligofectAMINE (Invitrogen) according to
manufacturer’s instructions. Twenty-four hours after trans-
fection, the cells were treated with 5 Amol/L gefitinib or
DMSO vehicle. After 0, 12, 24, 48, and 72 h of treatment,
both the suspension and the adherent cells were collected
for Western blot analysis, proliferation assay, and flow-
cytometric analysis.
Generation of MDA-MB-231-FOXO3a:ERCell Lines
For the generation of MDA-MB-231 cells stably expressing
FOXO3a(A3):ER* (24, 25), 10 Ag of pBabe-puromycin-
FOXO3a(A3):ER vector or empty vector was transfected
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into MDA-MB-231 cells using calcium phosphate precipita-
tion method (26). Cells were selected and maintained in the
presence of 1 Ag/mL puromycin (InvivoGen), and clonal cell
lines were generated.
Immunohistochemistry
Immunostaining was done on 4-Am sections of formalin-
fixed, paraffin-embedded blocks from patient’s tumor
samples obtained before and after 4 weeks of treatment
with 250 mg gefitinib per day (Iressa, AstraZeneca) as part of
a neoadjuvant clinical trial with patients with early-stage
breast cancer (9). The control group consisted of the patients
that had no treatment between biopsy and tumor resection.
Antigen retrieval was done by microwaving the slides in the
citrate buffer (pH 6.0). Primary antibody and FOXO3a 1:150
(Upstate) were applied overnight, and DAKO REAL
EnVision Detection System, Peroxidase/DAB+ (DAKO)
was used to visualize the staining. Intensity of FOXO3a
staining for nucleus and cytoplasm was evaluated sepa-
rately using 0 to 3 score system. A score of zero indicated
no staining relative to background, 1+ = weak staining,
Figure 1. Effect of gefitinib on
proliferation and cell cycle distribution
of a panel of breast cancer cell lines.
A, BT474, SKBR3, MCF7, MDA-MB-
453, and MDA-MB-231 cells were
treated with 5 Amol/L gefitinib for 0,
24, 48, and 72 h, collected, and
counted using Neubauer hemocytom-
eter under trypan blue exclusion.
Points, mean of three independent
experiments, each at least in dupli-
cate; bars, SD. Statistical analysis
has been done using Student’s t test.
*, P < 0.0001; **, P < 0.001; c,
P = ns. B, BT474, SKBR3, MCF7,
MDA-MB-453, and MDA-MB-231
cells were treated with 5 Amol/L
gefitinib for 0, 12, 24, 48, and 72 h,
fixed in ethanol, and stained with
propidium iodide, and DNA content
was determined by flow cytometry.
The percentage of cells in each phase
of the cell cycle (sub-G1, G0-G1, S,
and G2-M) is indicated. Representa-
tive data from two independent
experiments are shown.
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2+ = moderate staining, 3+ = strong staining. For com-
parison of staining, the results were quantified by calcula-
tion of separate H scores for nucleus and cytoplasm that
consider both staining intensity and the percentage of >cells
stained at a specific range of intensities. A complete H score
was calculated by summing the products of the percentage
cells stained at a given staining intensity (0–100) and the
staining intensity (0–3).
Statistical Analysis
For statistical evaluation, data were first analyzed for
normality of distribution using the Shapiro-Wilk and
Kolmogorov-Smirnov test. The equality of variances was
tested by using the Levene’s test. Significance of the differ-
ences between two independent samples has been estimated
using Student’s t test or Mann-Whitney U test. Changes in
staining intensity from pre- to posttreatment in control and
treatment groups were analyzed using mixed-design
ANOVA with post hoc Bonferroni test. The ANOVA design
was composed of one between-subjects factor (treatment art:
no treatment or gefitinib) and two within-subjects factors
(time: pretreatment/posttreatment; cellular localization:
nucleus/cytoplasm). Statistical tests were two sided, with
the effects reported as significant at P < 0.05. Statistical
analysis was done with Statistica 6.1 (StatSoft) software.
Results
Effect of Gefitinib on Proliferation of Human Breast
Cancer Cell Lines
The effect of gefitinib was evaluated on a panel of five
breast cancer cell lines, including BT474, SKBR3, MCF-7,
Figure 2. Changes in signal trans-
duction pathway induced by gefiti-
nib. A, protein lysates were prepared
from breast cancer cells after treat-
ment with 5 Amol/L gefitinib at the
time points indicated, and protein
expression levels were analyzed by
Western blotting using specific anti-
bodies. The Western blot results
shown represent the results from a
number of attempts, which showed
similar trends. Inhibition of phospho-
Akt (P-Akt ) correlates with inhibition
of phospho-FOXO3a (P-FOXO3a )
and induction of FOXO3a targets,
Bim and p27Kip1 in cells that are
sensitive to gefitinib but not in
nonsensitive cells. It should be noted
that these experiments are designed
to follow changes in protein expres-
sion during treatment, and because
different exposures were used for
different cell lines, no comparison
between cell lines can be made from
these blots. B, quantitative analysis
of P-FOXO3a, P-Akt, and P-ERK 1/2
protein expression. Columns, mean
results of two independent experi-
ments after normalizing the data to
t = 0 h; bars, SD. Statistical ana-
lysis has been done using Student’s
t test. *, P < 0.005; **, P <
0.001; ***, P < 0.05.
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MDA-MB-231, and MDA-MB-453. Cells were treated with
5 Amol/L gefitinib for 0, 24, 48, and 72 h, and then the cell
number was counted using a Neubauer hemocytometer
under trypan blue exclusion. Treatment of BT474 and SKBR3
cells with gefitinib resulted in a significant reduction of the
number of growing cells compared with nontreated cells
(P < 0.0001 and P < 0.001, respectively; Fig. 1A). Gefitinib
had no significant effect on the growth of MDA-MB-453,
MDA-MB-231, and MCF-7 at any time point tested (Fig. 1A).
Treatment with Gefitinib Causes G0-G1 Arrest and
Apoptosis in Sensitive but Not Resistant Cell Lines
To further examine the effect of gefitinib on cell
proliferation and survival, we analyzed the cell cycle phase
distribution by flow-cytometric analysis of propidium
iodide–stained cells after treatment with 5 Amol/L
gefitinib for 0, 12, 24, 48, and 72 h. The data shown in
Fig. 1B clearly shows that in the sensitive cell lines, BT474
and SKBR3, gefitinib induced G0-G1 arrest followed by
apoptosis, whereas treatment of MDA-MB-231, MDA-MB-
453, and MCF-7 cells with gefitinib did not elicit a cell
death response or induce discernible changes in cell-cycle
distribution at any time point (Fig. 1B).
EGFR Inhibition by Gefitinib Results in FOXO3a
Dephosphorylation in Sensitive and Nonresistant
Breast Cancer Cell Lines
To investigate the potential role of FOXO3a in mediating
cell cycle arrest and apoptotic response to the EGFR
inhibitor, we compared the changes in protein expression
of P-FOXO3a as well as P-Akt and P-ERK 1/2 in the five
breast carcinoma lines following treatment with 5 Amol/L
gefitinib for 0, 12, 24, and 48 h. In the sensitive cell lines,
BT474 and SKBR3, EGFR inhibition was associated with a
significant reduction in P-Akt (P < 0.001 and P < 0.05,
respectively) and significant decrease in P-FOXO3a protein
levels (P < 0.005), whereas in the gefitinib-insensitive cell
lines MDA-MB-231 and MCF-7, no significant decrease in
the level of P-Akt and P-FOXO3a could be detected (Fig. 2A
and B). For the other refractory line MDA-MB-453, gefitinib
significantly reduced P-Akt level (P < 0.05), but there was
no significant change in P-FOXO3a level. This finding
suggests that FOXO3a could be, in some cases, a better
indicator for gefitinib activity and response than its direct
upstream regulator Akt. There were also no significant
changes in total FOXO3a, Akt, and ERK levels in response
to gefitinib, indicating that gefitinib modulates the activity
of these signaling intermediates predominantly at post-
translational levels. Notably, in both the sensitive and
resistant cell lines, gefitinib treatment caused ERK dephos-
phorylation, suggesting that the ERK MAP kinase might
not be essential for the cytotoxic effects of gefitinib in breast
cancer cells (Fig. 2A and B). Furthermore, the ability of
gefitinib to inhibit ERK signaling in the insensitive cells
also implies that gefitinib resistance in breast cancer cell
lines is due to deregulation of downstream signals rather
Figure 3. Gefitinib causes nuclear translocation of FOXO3a in sensitive BT474 and SKBR3 cells, but not in resistant MCF7, MDA-MB-453, and MDA-
MB-231 cells as detected by confocal microscopy and Western blot analysis. A, BT474, SKBR3, MCF-7 MDA-MB-453, and MDA-MB-231 cells were
cultured on sterile coverslips and treated for 24 h with 5 Amol/L gefitinib or vehicle, before being fixed in 4% formaldehyde. FOXO3a was visualized with a
rabbit polyclonal antibody followed by the addition of Alexa 488 (green ) – labeled anti-rabbit antisera. 4¶,6-Diamidino-2-phenylindole (blue ) was also
applied to visualize the nuclei. B, nuclear and cytoplasmic lysates were prepared after treatment with 5 Amol/L gefitinib at the times indicated, and changes
in FOXO3a protein level were analyzed by Western blotting.
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than EGFR itself. We also obtained data showing that
similar results were obtained after treatment with 1 Amol/L
lapatinib in these breast carcinoma cell lines (data not
shown).
FOXO3a induces the expression of the cyclin-dependent
kinase inhibitor p27Kip1 and the BH3-only protein Bim in
breast cancer cells to mediate cell cycle arrest and cell
death, respectively (22, 27). To determine if decreased
phosphorylation of FOXO3a in response to gefitinib was
associated with its activation, we analyzed the expression
of the FOXO3a targets, p27Kip1 and Bim. As shown in Fig. 2,
there was an increase in p27Kip1 and Bim protein expression
in the sensitive BT474 and SKBR3 cell lines, but not in the
insensitive lines MDA-MB-231, MD-MB-453, and MCF-7
after gefitinib treatment.
Gefitinib Induces NuclearTranslocation of FOXO3a
It is well characterized that phosphorylation by Akt
relocates FOXO3a to the cytoplasm and inhibits its trans-
activation activity (18). To investigate further the mecha-
nism of action of gefitinib, we next studied the subcellular
localization of FOXO3a in response to gefitinib treatment
by confocal microscopy following staining with a FOXO3a-
specific antibody. In the untreated gefitinib-sensitive BT474
and SKBR3 cells, endogenous FOXO3a resided almost
exclusively in the cytoplasm, whereas 24 h after gefitinib
treatment, FOXO3a relocated predominantly to the nucleus
(Fig. 3A). Conversely, in the resistant MDA-MB-453, MDA-
MB-231, and MCF-7 cell lines, FOXO3a remained predom-
inantly in the cytoplasm before and after gefitinib treatment
(Fig. 3A). The change in FOXO3a localization was further
confirmed by Western blot analysis of nuclear/cytoplasmic
lysates. As shown in Fig. 3B, treatment of BT474 and SKBR3
cells with gefitinib resulted in a decrease in FOXO3a level
in the cytoplasm and a parallel increase in FOXO3a in the
nucleus. Consistent with the confocal microscopy findings,
little or no changes in cytoplasmic and nuclear distribution
of FOXO3a was detected in the insensitive cell lines after
gefitinib treatment (Fig. 3B). Together, these results suggest
that gefitinib induces FOXO3a dephosphorylation and
nuclear translocation in sensitive breast carcinoma cells
to mediate G0-G1 cell cycle arrest and apoptosis through
activating the expression of gene products.
Figure 4. Immunohistochemical staining
for FOXO3a of breast cancer tumor tissues.
A, tumor tissue sample obtained from breast
cancer patients before and 4 wk after treat-
ment with gefitinib were stained with
FOXO3a antibody. Control group of patients
received no treatment between primary biop-
sy and subsequent surgical tumor resection.
In the control group, cytoplasmic staining can
be observed in both pre- and post-cases,
whereas in the gefitinib-treated group, cyto-
plasmic staining in pretreatment cases
changes to predominantly nuclear staining
after treatment (post ; magnification, 200).
B, statistical analysis using a mixed-design
ANOVA with post hoc Bonferroni test
revealed significant increase in FOXO3a nu-
clear staining intensity with a concomitant
decrease in cytoplasmic staining after gefitinib
treatment, whereas no such changes were
observed in the control group.
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Gefitinib Induces FOXO3a Nuclear Accumulation in
Breast Cancer Patients’ Samples
To extend our in vitro findings, we analyzed by immu-
nohistochemical staining the expression and subcellular
localization of FOXO3a in cancer patient samples obtained
before and after 4 weeks of gefitinib treatment, as part of
a recently carried out presurgical study in patients with
early breast cancer (9). Staining was done on 13 cases that
included patients with tumor size reduction more than
1 cm measured by ultrasonography. As the control group,
we used tumor tissue sections from 14 patients that had no
treatment between biopsy and surgical tumor excision
(Fig. 4A). After estimating staining intensity using H scores
for nucleus and cytoplasm separately, the results were
analyzed using a mixed-design ANOVA with a post hoc
Bonferroni test (Fig. 4B). There was no significant difference
in total (nuclear plus cytoplasmic) FOXO3a levels between
treatment groups (i.e., control and treated groups, P = 0.64)
and times of treatment (i.e., pre- and posttreatment, P =
0.116). The analysis also showed no evidence of interaction
between treatment and time, indicating that there are no
significant differences in total FOXO3a levels before and
after treatment (P = 0.58). However, the analysis showed
that there was a significantly higher intensity of FOXO3a
staining in the cytoplasm than the nucleus (P < 0.001).
FOXO3a staining was stronger in the cytoplasm than the
nucleus in control group, whereas no such differences were
noted in the treated group, resulting in a significant
interaction between subcellular localization and treatment
groups (P < 0.001). When analyzing the interaction between
time of treatment and subcellular localization, there was
a significant increase in nuclear but not cytoplasmic
FOXO3a staining (P < 0.001). Addition of treatment as a
third variable to the analysis resulted in a significant triple
interaction (time of treatment  subcellular localization 
treatment groups; P < 0.001). Post hoc test was done to break
down this interaction, and the analysis showed that before
treatment, cytoplasmic staining was significantly stronger
than nuclear staining in both the control and treated groups
(P < 0.001 for both). Furthermore, after gefitinib treatment,
there was a significant increase in nuclear staining intensity
(P < 0.001), with a concomitant decrease in cytoplasmic
staining intensity (P = 0.005), whereas in the control group,
there were no such changes in staining intensity in both
nucleus and cytoplasm. These findings suggested that
gefitinib treatment causes subcellular translocation of
FOXO3a from cytoplasm to nucleus in breast tumor cells
of cancer patients sensitive to the drug, confirming our
Figure 5. Effect of FOXO3a-specific siRNA on expression of FOXO3a, p27Kip1 protein level, and cell proliferation in response to gefitinib treatment in
BT474 cells. BT474 cells transfected with control siRNA pool or FOXO3a siRNA pool were treated with gefitinib for the times indicated. A, protein lysates
were prepared at the times indicated and analyzed by Western blotting. B, cell counts at times indicated following gefitinib treatment. Columns, mean of
three independent experiments, each in triplicate; bars, SD. Statistical evaluation was done using Student’s t test. *, P < 0.005; **, P < 0.001; ***,
P < 0.0001. C, parallel cells were also fixed in ethanol, and the DNA content was analyzed after propidium iodide staining by flow cytometry. The
percentage of cells in each phase of the cell cycle (sub-G1, G0-G1, S, and G2-M) are indicated. Representative data from three independent experiments are
shown. D, comparison of proliferating cells, as judged by total cells in S-G2-M phases, and apoptotic sub-G1 cells between BTB474 cells transfected with
FOXO3a-specific or nonspecific siRNA during gefitinib treatment. Columns, mean of the three independent experiments; bars, SD. Statistical evaluation
was done using the Mann-Whitney U test. *, P < 0.05, statistically significant differences.
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findings from the tissue culture cells. Nevertheless, we were
unable to study the contribution of FOXO3a in gefitinib
resistance in these samples because of the fact that almost
all patients responded to gefitinib because these were pri-
mary breast cancer patients without prior drug treatments.
Silencing of FOXO3a by siRNAResults in a Reduction
of Gefitinib-Induced Cell Death and ProliferativeArrest
To show that FOXO3a has an essential role in response
to gefitinib treatment, we transfected the gefitinib-sensitive
BT474 breast carcinoma cells with either a FOXO3a-specific
siRNA or a nonspecific control siRNA pool and studied the
proliferation of these cells after gefitinib treatment. Western
blot analysis showed that the FOXO3a-specific siRNA, but
not control siRNA, knocked down the expression of endo-
genous FOXO3a in the BT474 cells (Fig. 5A). Moreover,
the FOXO3a-specific siRNA, but not the control siRNA,
inhibited the induction of p27Kip1 and also reduced the
induction of Bim by gefitinib treatment. Consistent with
our earlier results (Fig. 1A), treatment of control siRNA-
transfected BT474 cells with gefitinib resulted in a dramatic
decrease in a number of growing cells (P < 0.001; Fig. 5B).
Conversely, the gefitinib-induced decrease in cell prolifer-
ation was overcome in BT474 cells treated with FOXO3a
targeting siRNA pool (P < 0.001), indicating that FOXO3a
is responsible for the effect of gefitinib on cell growth
(Fig. 5B). Consistent with this, cell cycle analysis showed
that silencing of FOXO3a by siRNA can partially rescue cells
from gefitinib-induced proliferative arrest and cell death.
This is evident from the increase in the fraction of cells in
S and G2-M phases (P < 0.05 at 72 h) and reduction in the
apoptotic sub-G1 fraction (P < 0.05 at 72 h) in siFOXO3a-
transfected BT474 cells compared with control cells (Fig. 5C
and D). These results suggested that gefitinib targets
FOXO3a to mediate cell death and proliferative arrest in
sensitive breast carcinoma cells.
Reintroduction of FOXO3a Restores Proliferative
Arrest and Sensitivity in Gefitinib-Resistant Breast
Cancer Cells
To test the hypothesis that FOXO3a dephosphorylation
and nuclear translocation crucially determine sensitivity to
gefitinib, we introduced an inducible form of active
FOXO3a, FOXO3a(A3):ER*, in which all three Akt phos-
phorylation sites were mutated to alanine into the highly
resistant ER-negative breast cancer cell line MDA-MB-231.
Addition of 4-hydroxytamoxifen (4-OHT) to these MDA-
MB-231-FOXO3a:ER cells results in the rapid nuclear
translocation and induction of FOXO3a activation, recapi-
tulating the FOXO3a dephosphorylation and nuclear
accumulation following gefitinib treatment (Supplementary
Fig. S1).3 Additionally, we found that although p27Kip1
Figure 6. Effect of FOXO3a(A3):ER induction and gefitinib treatment on FOXO3a and p27Kip1 expression and cell proliferation in MDA-MB-231 cells.
MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 wild-type cells were treated with 4OHT and/or gefitinib for the indicated times. A, cell lysates were
prepared at the times indicated, and the expression of FOXO3a(A3):ER, p27Kip1, Bim, and h-tubulin was analyzed by Western blotting. B, cells were fixed
at 0, 24, and 48 h after treatment, and cell cycle phase distribution was analyzed by flow cytometry after propidium iodide staining. The percentages of
cells in each phase of the cell cycle (sub-G1, G0-G1, S, and G2-M) are indicated. Representative data from three independent experiments are shown. C, cell
counts at times indicated following gefitinib treatment. Points, mean of two independent experiments each in triplicate; bars, SD. Statistical analysis has
been done using Student’s t test. *, P < 0.05, for MDA-MB-231 versus MDA-MB-231 FOXO3a:ER; **, P < 0.01, for MDA-MB-231 FOXO3a:ER versus
MDA-MB-231 FOXO3a:ER + gefitinib.
3 Supplementary material for this article is available at Molecular Cancer
Therapeutics Online (http://mct.aacrjournals.org/).
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is up-regulated upon activation of FOXO3a in the MDA-
MB-231-FOXO3a:ER cells, Bim expression is not induced
(Fig. 6A). Cell cycle analysis showed that the reintroduction
of an activated mutant of FOXO3a in MDA-MB-231 restored
proliferative arrest, indicating that the failure of FOXO3a
dephosphorylation and nuclear translocation in response to
gefitinib treatment is essential for conferring resistance to
MDA-MB-231 cells (Fig. 6B). More importantly, our results
showed that despite gefitinib alone having no effect on the
cell cycle progression of MDA-MB-231 cells, gefitinib
further reduced cells in the S and G2-M phase compared
with FOXO3a induction alone, suggesting that FOXO3a
activation resensitizes resistant cells to gefitinib (Fig. 6B).
We also evaluated the effect of FOXO3a induction on the
growth of MDA-MB-231 cells by cell counting. Consistent
with our previous results (Fig. 1A), treatment of MDA-
MB-231 cells with gefitinib did not affect cell growth
(Fig. 6C). However, induction of FOXO3a activity by
tamoxifen in MDA-MB-231-FOXO3a:ER cells significantly
decreased cell proliferation starting from the 48-h time point
(P < 0.05), and additional treatment with gefitinib further
significantly reduced cell growth (P < 0.01; Fig. 6C). It is
notable that FOXO3a induction in MDA-MB-231 cells
activated cell cycle arrest but little apoptosis. The reason
for this is unclear; however, one potential explanation could
be that in MDA-MB-231 cells, expression of the proapop-
totic FOXO3a target Bim is deregulated. Consistent with this
idea, we have shown here and previously that Bim
expression is undetectable in MDA-MB-231 cells in
response to different apoptotic stimulations (22, 27). Taken
together, these results confirmed that not only is FOXO3a an
integral signaling molecule in the anti-mitogenic action of
gefitinib, its function also determines the sensitivity to
gefitinib in human breast cancer cells.
Discussion
EGFR plays a central role in the development and
progression of a number of common malignancies of
epithelial origins, including breast, colon, pancreatic, and
lung cancers (28–30). As a consequence, EGFR has
emerged as an obvious molecular target for cancer
therapy, with monoclonal antibodies (e.g., Cetuximab)
and small-molecule TKIs, such as gefitinib (Iressa) being
developed to specifically block EGFR signaling (5, 31).
These anti-EGFR agents have shown promising outcomes
in initial preclinical and clinical settings; however, there is
also a high rate of de novo and acquired resistance, which
limits the efficacy of such treatments (32). Nevertheless,
lapatinib, the dual EGFR and HER2 inhibitor, has been
shown to improve disease-free survival in advanced breast
cancer patients (33).
In pulmonary adenocarcinoma, resistance-related sec-
ondary mutations (e.g., T790M) in EGFR have been shown
to occur after initial gefitinib treatment, but these mutations
are uncommon and, therefore, unlikely to be the major
cause of acquired resistance in breast cancer. Consistent
with this, the immediate signaling is intact in most
gefitinib- and lapatinib-resistant breast cancer cells, indi-
cating that signaling events further downstream of EGFR
determine the sensitivity to these anti-EGFR agents. We
have screened a panel of breast carcinoma cell lines
(data not shown) and identified two cell lines, BT474 and
SKBR3, which are sensitive to gefitinib treatment. Using
these two gefitinib-sensitive as well as three other resistant
breast carcinoma cell lines (i.e., MCF7, MDA-MB-231, and
MDA-MB-453), we have shown that gefitinib targets the
transcription factor FOXO3a to mediate cell cycle arrest
and cell death in sensitive breast cancer cells, BT474 and
SKBR3. In the sensitive cells, gefitinib or lapatinib
treatment causes cell cycle arrest predominantly at the
G0-G1 phase and apoptosis, which is associated with
FOXO3a dephosphorylation at Akt sites and nuclear
translocation, whereas in the resistant cells, FOXO3a stays
phosphorylated and remains in the cytoplasm. These
results were verified by immunohistochemical staining of
breast cancer patient biopsy samples. Although this pilot
in vivo study is limited by a relatively small sample size,
the results show that nuclear expression of FOXO3a is
significantly increased in patients treated with gefitinib
compared with those untreated. Furthermore, silencing of
the endogenous FOXO3a expression by siRNA at least
partially rescued the highly sensitive carcinoma cell line
BT474 from undergoing proliferative arrest and apoptosis
in response to gefitinib, suggesting that the induction of
FOXO3a expression has a direct role in mediating the effect
of gefitinib on cell proliferation and survival. A number of
other findings also suggested that activation of FOXO3a
plays an important role in determining sensitivity to
gefitinib. First, gefitinib induced FOXO3a dephosphoryla-
tion and nuclear translocation only in the sensitive cells,
whereas other signaling events, such as ERK dephosphor-
ylation, proceeded normally in both sensitive and resistant
cells. Second, expression of an inducible, constitutively
dephosphorylated FOXO3a mutant was sufficient to
partially restore sensitivity to gefitinib in the highly
resistant MDA-MB-231 cells. These results are consistent
with previous published data showing that lapatinib also
targets FOXO3a in breast cancer cells to induce apoptosis
(34, 35). Furthermore, blockage of EGFR and HER2
signaling using monoclonal antibodies cetuximab and
trastuzumab also induces nuclear translocation of FOXO3a
(36). Taken together, our data and those of others showed
that FOXO3a is an essential target of anti-EGFR and HER2
therapies in breast cancer. However, because silencing of
FOXO3a expression in BT474 cells does not completely
rescue the cells from apoptosis, it is reasonable to conclude
that other mechanisms can also be involved in determining
response to gefitinib treatment.
A previous study using BT474 as cell culture model has
attributed the cytotoxic effect of lapatinib solely to their
ability to inhibit ERB2 and not EGFR, based on the
observation that EGFR could not be detected in these cells
(34). Despite this report, we show that BT474 is sensitive
to gefitinib, which only targets EGFR and not ERB2. In
support of our findings, others have previously established
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that EGFR is expressed in BT474 breast carcinoma cells
(37). Overexpression of EGFR is only one of the mecha-
nisms responsible for the activation of EGFR signaling
pathway. The absence of direct correlation between EGFR
expression levels and response to the treatment with EGFR
inhibitors has been previously reported (38). Consistent
with this, our data show that MDA-MB-231 cells express
high EGFR levels and are resistant to gefitinib treatment,
whereas BT474 cells have low EGFR expression, but are
highly sensitive to gefitinib. Similarly, neither ERK 1/2 nor
Akt activity has been proven to be a reliable predictor of
gefitinib response (39). These studies are in accordance
with our results showing that a decrease in phospho-ERK
1/2 and phospho-Akt does not necessarily associate with
response to gefitinib. Although Akt plays an important
role in the regulation of FOXO3a activity, it is not the only
kinase that can phosphorylate and deactivate FOXO3a.
For example, serum- and glucocorticoid-inducible kinase
(SGK) can also phosphorylate FOXO3a at Thr32 (40). This
can explain the failure of gefitinib to reduce FOXO3a phos-
phorylation in MDA-MB-453 cells despite an inhibitory
effect on Akt.
Gefitinib is able to sensitize breast cancer cells to
chemotherapy-induced apoptosis (31), which could be
due to the fact that gefitinib and chemotherapeutic agents
mediate cell death through overlapping signaling path-
ways. Consistent with this idea, we have previously shown
that chemotherapeutic drugs, such as paclitaxel, mediate
cell cycle arrest and apoptosis through enhancing FOXO3a
activity in breast cancer cells (22, 27). Because gefitinib and
lapatinib are, in general, effective, safe, and well-tolerated
therapeutic agents (41), it may be beneficial to concurrent
chemotherapy and gefitinib or lapatinib treatments.
In summary, the present study helps to define the
mechanism by which gefitinib mediates cell cycle arrest
and apoptosis in breast cancer. It also reveals that the
transcription factor FOXO3a could be a useful early
biomarker for predicting outcomes and for monitoring
anti-EGFR and HER2 therapies as well as a biomarker for
the clinical course of anti-EGFR/HER2 agents. Moreover,
our results suggest that targeting FOXO3a in breast cancer
could potentially improve the effectiveness of anti-EGFR/
HER2 agents, such as gefitinib and lapatinib.
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